The Keytruda Patent Cliff: Pricing Dynamics Following Biosimilar Competition
Summary
As a blockbuster therapy in immuno-oncology, Keytruda has undoubtedly established itself as one of the most clinical and commercially successful medicines across the global biopharmaceutical landscape. Its upcoming loss of exclusivity therefore represents one of the most consequential and prominent events in the global oncology market, with far-reaching pricing implications.Table of Contents
- Key findings
- Keytruda's patent wall
- Analysis of Keytruda price dynamics following LoE
- Disclaimer
